Recent advances in triple negative breast cancer: the immunotherapy era

Abstract Background Several accomplishments have been achieved in triple-negative breast cancer (TNBC) research over the last year. The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. Nevertheles...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Antonio Marra, Giulia Viale, Giuseppe Curigliano
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2019-05-01
Edice:	BMC Medicine
Témata:	Triple-negative breast cancer Immunotherapy PD-L1 Biomarkers Checkpoint inhibitors
On-line přístup:	http://link.springer.com/article/10.1186/s12916-019-1326-5
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!